Levodopa Withdrawal Presenting as Fever in a Critically Ill Patient Receiving Concomitant Enteral Nutrition

Abstract

Nutritional protein may decrease levodopa absorption and has resulted in withdrawal and neuroleptic malignant-like syndromes in critically ill patients. A 72-year-old male was admitted with shortness of breath. His medical history included Parkinson’s disease for over 30 years for which he took carbidopa/levodopa 5 times daily. The patient’s home medications were continued. On day 2, he was intubated and transferred to the intensive care unit (ICU). He was extubated the next day and reintubated on day 4. Enteral nutrition was initiated at 85 mL/h overnight. The patient’s carbidopa/levodopa was administered to limit coadministration with nutrition. Throughout his ICU stay, the patient did not demonstrate changes in mental status. Despite resolution of his pneumonia, he developed fever after administration of one dose overlapping with nutrition, with defervescence throughout the rest of the day. On hospital day 10, that dose was empirically increased. After this dosing change, the patient failed to develop fever during the rest of his hospital stay. On day 16, the patient was discharged to a long-term care facility without any other complications. Our case highlights the interaction between levodopa and enteral nutrition and the potential of fever as the sole sign of withdrawal.

Keywords

carbidopa/levodopa withdrawal critically ill fever

Get full access to this article

View all access options for this article.

References

Connolly

Lang

. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670–1683.

Mizuno

Takubo

Mizuta

. Malignant syndrome in Parkinson’s disease: concept and review of the literature. Parkinsonism Relat Disord. 2003;9(suppl 1):s3–s9.

Gibb

Griffith

. Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome. Postgrad Med J. 1986;62(723):59–60.

Man

. An uncommon adverse effect of levodopa withdrawal in a patient taking antipsychotic medication: neuroleptic malignant-like syndrome. Hong Kong Med J. 2011;17(1):74–76.

Cooper

Brock

McDaniel

. Interaction between levodopa and enteral nutrition. Ann Pharmacother. 2008;42(3):439–442. doi:10.1345/aph.1K450.

Bonnici

Ruiner

St-Laurent

. An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay. Ann Pharmacother. 2010;44(9):1504–1507. doi:10.1345/aph.1P242.

Koller

Hubble

. Levodopa therapy in Parkinson’s disease. Neurology. 1990;40(suppl 3):40–47.

Lennernas

Nilsson

Sten-Magnus

. The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. Br J Clin Pharmacol. 1993;35(3):243–250.

Karstaedt

Pincus

. Protein redistribution diet remains effective in patients with fluctuating parkinsonism. Arch Neurol. 1992;49(2):149–151.

10.

Pincus

Barry

. Influence of dietary protein on motor fluctuations in Parkinson’s disease. Arch Neurol. 1987;44(3):270–272.

11.

Naranjo

Busto

Sellers

. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.

12.

Guerrera

Caroff

Cohen

. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011;72(9):1222–1228.

13.

Sinemet® [package insert]. Morgantown, WV: Mylan Pharmaceuticals, Inc; 2014.

14.

Khor

Hsu

. The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson’s disease. Curr Clin Pharmacol. 2007;2(3):234–243.

15.

White

Bradnam

. Levodopa. In: White

, ed. Handbook of Drug Administration via Enteral Feeding Tubes. 3rd ed. London, UK: Pharmaceutical Press; 2015:403.

16.

Nyholm

Askmark

Gomes-Trolin

. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol. 2003;26(3):156–163.

17.

Olanow

Kieburtz

Odin

. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141–149.

18.

O’Grady

Barie

Bartlett

. Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Crit Care Med. 2008;36(4):1330–1349.

19.

Patel

Gallagher

. Drug fever. Pharmacotherapy. 2010;30(1):57–69.

20.

Grattagliano

Portincasa

Mastronardi

. Esomeprazole-induced central fever with severe myalgia. Ann Pharmacother. 2005;39(4):757–760.

21.

Rybak

Lomaestro

Rotschafer

. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82–98.